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Abstract
Background: This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan
when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of
this combination as first-line therapy in patients with advanced colorectal cancer.
Methods: Sixty-three patients received irinotecan (250 or 300 mg/m2, 30- to 90-minute intravenous infusion on day 1),
immediately followed by folinic acid (20 mg/m2/day) and 5-fluorouracil (425 mg/m2, 15-minute bolus infusion) days 1 to
5, every four weeks.
Results: Diarrhoea was dose limiting at 300 mg/m2 irinotecan in combination with 5-fluorouracil and folinic acid, and
this was determined to be the maximum tolerated dose. Grade 3–4 neutropenia was the most frequently reported
toxicity. The recommended dose of irinotecan for the phase II part of the study was 250 mg/m2. The response rate for
the evaluable patient population was 36% (13/36), and 44% (16 patients) had stable disease (including 19% of minor
response). For the intention-to-treat population, the response rate was 29% (14/49) and 35% (17 patients) stable disease
(including 14% of minor response). The median time to progression was 7.0 months and the median survival was 12.0
months. Grade 3–4 non-haematological drug-related toxicities included delayed diarrhoea, stomatitis, fatigue, and
nausea/vomiting. There were three deaths due to septic shock that were possibly or probably treatment-related.
Conclusions: This regimen of irinotecan in combination with the Mayo Clinic schedule of bolus 5-fluorouracil/folinic
acid every four weeks showed activity as first-line therapy in patients with advanced colorectal cancer. In keeping with
other published results of studies using bolus 5-fluorouracil combined with irinotecan, the use of this regimen is limited
by a relatively high rate of grade 3–4 neutropenia, and the combination of irinotecan and infusional 5-fluorouracil / folinic
acid should remain the regimen of first choice.
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Background
Until recently, 5-fluorouracil (5-FU) in combination with
folinic acid (FA) has been the mainstay of treatment for
advanced colorectal cancer (CRC) [1,2]. Of the numerous
schedules and doses of 5-FU investigated, the Mayo Clinic
bolus schedule, in which both 5-FU and FA are injected
daily for five days every four weeks [3-5], emerged as one
of the most widely used schedules worldwide for the first-
line treatment of advanced CRC.
Irinotecan (CPT-11, Campto®) is an S-phase specific deriv-
ative of camptothecin, which interferes with DNA replica-
tion and cell division inhibiting topoisomerase I [6].
Irinotecan demonstrated antitumour activity against met-
astatic CRC when used alone either as first-line treatment
[7-9] or as second-line treatment after the failure of 5-FU
[9-12], with overall response rates ranging from 13% to
32%. In randomised phase III trials, irinotecan adminis-
tered second-line prolonged survival significantly when
compared with either best supportive care [13] or infu-
sional 5-FU/FA [14]. The most frequently reported adverse
events associated with irinotecan are neutropenia,
delayed diarrhoea, acute cholinergic syndrome, alopecia,
fatigue, nausea and vomiting [12].
Early studies in which irinotecan was combined or alter-
nated with 5-FU/FA regimens showed promising first-line
efficacy in advanced CRC [15-19]. Two studies had
assessed the feasibility of irinotecan (administered every
three weeks in the European study or weekly for four
weeks followed by two weeks' rest in the US study) alter-
nating with the Mayo Clinic schedule [16,17]. Seventy
patients [16] and 33 patients [17] were treated and the
overall response rate was around 30%, with a median
time to progression of seven months in both studies. The
safety profile was satisfactory without overlapping toxici-
ties. These data, coupled with the emerging data from the
US and European phase III trials [20,21], suggested that a
study of irinotecan in combination with the Mayo Clinic
schedule every four weeks was warranted.
The present phase I/II study was designed to determine
the maximum tolerated dose (MTD), the recommended
dose and the safety profile of irinotecan when combined
with the 5-FU/FA Mayo Clinic schedule every four weeks
in the treatment of advanced CRC. The antitumour activ-
ity of this combination was also evaluated.
Methods
Patient eligibility
Patients with histologically proven, measurable, advanced
adenocarcinoma of the colon or rectum, with no poten-
tially resectable metastases, were eligible for inclusion in
the study. Other inclusion criteria were: age between 18
and 75 years; a World Health Organization (WHO) per-
formance status (PS) 0–2; a life expectancy >3 months;
adequate haematological function (haemoglobin ≥10 g/
dL, neutrophils ≥2 × 109/L and platelets ≥150 × 109/L);
satisfactory renal and hepatic functions (total bilirubin
≤1.25 × upper normal limit [UNL], creatinine ≤1.25 ×
UNL, aspartate aminotransferase [ASAT] and alanine ami-
notransferase [ALAT] ≤3 × UNL; or in the case of liver
metastases: total bilirubin ≤1.5 × UNL, ASAT and ALAT ≤5
× UNL); no prior chemotherapy or only (neo) adjuvant
chemotherapy completed more than six months prior to
study entry, and no radiotherapy within the four weeks
prior to study entry. Exclusion criteria included: evidence
of brain metastases, current infection, unresolved bowel
obstruction or sub-acute obstruction, uncontrolled
Crohn's disease or ulcerative colitis, and a current history
of chronic diarrhoea. This study was approved by the local
Ethics Committees of each centre, and conducted in
accordance with the Declaration of Helsinski. All patients
provided written informed consent. Pretreatment evalua-
tions included a complete medical history and physical
examination, complete blood cell count and blood chem-
istry, electrocardiogram (ECG), complete tumour imaging
(X-ray, computed tomography, ultrasound) performed
within three weeks before first infusion, and an assess-
ment of tumour markers. The first treatment administra-
tion was made within eight days of registration for the
study.
Treatment
Irinotecan (Campto®) was supplied by Aventis Pharma
(Antony, France) as a sterile solution of 20 mg/ml in 5 ml
vials. 5-FU and FA were used in commercially available
formulations. Irinotecan (starting at a dose of 250 mg/
m2) was administered as a 30- to 90-minute intravenous
[IV] infusion on day 1, immediately followed by FA 20
mg/m2/day IV bolus followed by 5-FU at a fixed dose of
425 mg/m2/day IV bolus, on days 1–5. All patients
received a 15-minute bolus infusion of 5-FU/FA. The
treatment was administered every four weeks up until dis-
ease progression, unacceptable toxicity or withdrawal of
patient consent.
Concomitant medication included subcutaneous atro-
pine 0.25 mg as curative treatment for severe cholinergic
symptoms, including early diarrhoea. For the treatment of
delayed diarrhoea, high-dose loperamide (2 mg every two
hours for at least 12 hours) was given as soon as the first
liquid stool occurred and continued for up to 12 hours
after the last liquid stool, without exceeding a total treat-
ment duration of 48 hours. If the diarrhoea persisted for
more than 48 hours despite loperamide treatment, or in
the case of severe diarrhoea or diarrhoea associated with
vomiting, fever or severe neutropenia, patients received a
seven-day course of prophylactic broad spectrum oral
antibiotics (fluoroquinolone or cotrimoxazole) and wereBMC Cancer 2004, 4:36 http://www.biomedcentral.com/1471-2407/4/36
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hospitalised for rehydration. Patients with febrile neutro-
penia had to be hospitalised to receive IV antibiotic
therapy.
Study design
Phase I study
The starting dose of irinotecan was 250 mg/m2 (dose level
I) and the subsequent planned dose levels were 300 mg/
m2 (dose level II) and 350 mg/m2 (dose level III). At least
three consecutive patients were to be entered at each dose
level with a one-week interval between the entry of the
first patient and the next two patients. If one out of three
patients at one dose level experienced a dose-limiting tox-
icity (DLT) in the first cycle, at least three more patients
were entered at the same dose level. If three out of six
patients experienced the same DLT, this dose level was
considered to be the MTD of irinotecan in this combina-
tion. In the absence of DLT, the next dose level was
explored. Once the MTD, as defined above, was reached,
the dose immediately below the MTD was explored for
determination of the recommended dose. At least six
patients were to be included at the MTD and at the recom-
mended dose. Intra-patient dose escalation was not
allowed. DLT during the first cycle was defined as the
occurrence of any grade 3 or 4 non-haematological toxic-
ity (except alopecia), platelets <25 × 109/L, symptomatic
thrombocytopenia (haemorrhage), febrile neutropenia
(fever ≥38.0°C with concomitant grade 3–4 neutropenia
in the absence of documented infection), grade 3–4 infec-
tion, grade 4 neutropenia ≥7 days, grade 3–4 neutropenia
associated with severe infection. Second and further cycles
of treatment were administered when the neutrophil
count was ≥1.5 × 109/L, platelets ≥100 × 109/L and non-
haematological toxicity (except alopecia) ≤grade 2, other-
wise treatment had to be delayed but not for more than
two weeks. If the delay was greater than two weeks, the
patient was withdrawn from the study.
Phase II study
According to the optimal two-stage Simon design [22]
used to define the total number of patients required to
detect the activity of the treatment, up to 43 evaluable
patients had to be included in the study. Dose reductions
of 20% for irinotecan and 5-FU were planned in case of
grade 3–4 haematological and/or non-haematological
toxicities. There was no dose reduction schedule for FA. As
for the phase I part of the study, if the treatment delay was
greater than two weeks, the patient was withdrawn from
the study.
Relative dose intensities (RDI, the ratio between the actual
dose delivered and the planned dose) for the different
components of the treatment were regimen were calcu-
lated for both the phase I and phase II parts of the study.
Toxicity and response evaluation
Toxicity, graded according to National Cancer Institute
Common Toxicity Criteria (NCI-CTC) version 1, was
assessed by clinical examination every cycle, weekly for
haematology and every two cycles for biochemistry.
Tumour responses were assessed every eight weeks (or two
cycles of treatment) using the same method of assessment
used at baseline, and according to WHO criteria.
Responses were defined as follows: complete response
(CR), partial response (PR), minor response (MR), stable
disease (SD), and progressive disease (PD). The overall
response rate was defined as the percentage of patients
with a CR or PR. The duration of response, in responding
patients, was calculated from the date of first infusion to
the date of documented progression. The time to disease
progression (TTP) was calculated from the time of the first
infusion to the date of documented progression or death
due to malignant disease. Deaths for other reasons than
malignant disease were censored.
Statistical analysis
Analyses were performed using SAS® Software version 8.0
within Windows. The primary end-point of the phase I
part of the study was to analyse the DLT observed during
the first cycle and to determine the MTD of irinotecan in
combination with the 5-FU/FA Mayo Clinic schedule. The
secondary objectives were to determine the recommended
dose of irinotecan for the phase II part of the study and the
safety profile of the combination regimen. In the phase II
part of the study, the response rate was reported within
95% confidence intervals (CI). Efficacy analyses were per-
formed for both the intent-to-treat (ITT) and evaluable
(eligible patients with measurable lesion, who had
received a minimum of two cycles of treatment, i.e. eight
weeks on study) populations.
The Kaplan-Meier method was used to analyse TTP and
overall survival. Safety analyses were performed on all
patients receiving at least one administration of
irinotecan.
Results
Patient characteristics
Between June 19, 1999 and March 26, 2001, 63 patients
from three countries (Austria, South Africa, and United
Kingdom) were entered: 14 patients in the phase I part of
the study and 49 patients in the subsequent phase II part
of the study (Table 1). Four patients were not eligible in
the phase II part of the study due to the absence of ade-
quate biochemical/haematological function (one of these
patients also had no measurable lesion and one had
received adjuvant chemotherapy less than six months
prior to study entry). Demographic and baseline disease
characteristics are listed in Table 1. Seven men and 7
women with a median age of 59 years entered the phase IBMC Cancer 2004, 4:36 http://www.biomedcentral.com/1471-2407/4/36
Page 4 of 10
(page number not for citation purposes)
part of the study. Thirty-three men and 16 women with a
median age of 63 years entered the phase II part of the
study. In both parts of the study, the majority of patients
had a WHO PS of 1 and two organs involved (median 2,
range 1–4), with the liver being the most common site of
metastatic disease. Most patients underwent prior surgery
(86% in both parts of the study). Prior radiotherapy was
given to 21% of phase I patients and to 29% of phase II
patients. Prior adjuvant chemotherapy had been adminis-
tered to 29% and 24% of phase I and phase II patients,
respectively.
Maximum tolerated dose, recommended dose, phase I 
part of the study
Six patients received irinotecan at dose level I (250 mg/
m2). Eight patients received irinotecan at dose level II
(300 mg/m2). DLTs in the first cycle of treatment are
shown in Table 2. The MTD was determined to be irinote-
can 300 mg/m2 combined with 5-FU 425 mg/m2 and FA
20 mg/m2. At this dose level, a total of four patients (out
of eight) experienced a grade 3 or 4 non-haematological
toxicity, comprising diarrhoea (three patients), fatigue or
pain (one patient each). The haematological DLT was
grade 3–4 neutropenia with severe infection (one
patient). The recommended dose level for irinotecan was
defined as 250 mg/m2 combined with 5-FU 425 mg/m2
and FA 20 mg/m2. Of the six patients treated at this dose
level, four experienced a non-haematological grade 3–4
toxicity, comprising stomatitis, nausea, fatigue, diarrhoea
or pulmonary toxicity. One patient also experienced
febrile neutropenia.
Treatment compliance
Phase I
In total, 60 cycles of irinotecan combined with 5-FU/FA
were administered to 14 patients (median number of
Table 1: Patient characteristics
Characteristics* Phase I (n = 14) Phase II (n = 49)
Eligible 14 (100%) 45 (92%)
Evaluable 11 (79%) 36 (73%)
Median age (range) years 59.0 (30.0–69.0) 63.0 (37.0–71.0)
Sex
Male 7 (50%) 33 (67%)
Female 7 (50%) 16 (33%)
WHO performance status
0 4 (29%) 14 (29%)
1 10 (71%) 31 (63%)
20 4  ( 8 % )
Primary tumour site
Colon 9 (64%) 17 (35%)
Rectum 4 (29%) 22 (45%)
Colon rectosigmoid 1 (7%) 10 (20%)
Organ involved
Median number 2 (1–4) 2 (1–4)
Liver 10 (71%) 42 (86%)
Lung 6 (43%) 17 (35%)
Lymph node 1 (7%) 10 (20%)
Other soft tissue 0 11 (22%)
Abdominal cavity 2 (14%) 3 (6%)
Peritoneum 1 (7%) 0
Bone 1 (7%) 0
Skin 0 1 (2%)
Other 2 (14%) 5 (10%)
Prior therapy
Surgery 12 (86%) 42 (86%)
Radiotherapy 3 (21%) 14 (29%)
Adjuvant chemotherapy 4 (29%) 12 (24%)
Surgery + radiotherapy 3 (21%) 12 (24%)
Surgery + chemotherapy 4 (29%) 12 (24%)
Radiotherapy + chemotherapy 2 (14%) 7 (14%)
Surgery + radiotherapy + chemotherapy 2 (14%) 7 (14%)
*N (%) unless otherwise stated. WHO = World Health Organization.BMC Cancer 2004, 4:36 http://www.biomedcentral.com/1471-2407/4/36
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cycles four, range, 1–8). Six cycles (10%) were delayed
(22% at dose level I and 5% at dose level II), and in two
cycles (3%), the dose was reduced due to non-haemato-
logical toxicity (one cycle) and prescription error (one
cycle).
Phase II
In total, 218 cycles were administered to 49 patients
(median four cycles, range, 1–12). The median RDI was
90% (range, 52–110%) for irinotecan, 88% (range, 19–
108%) for 5-FU and 98% (range, 20–135%) for FA. Atotal
of 22 cycles (10%) had to be delayed due to haematolog-
ical (seven cycles) and non-haematological toxicity (six
cycles), non-study-related adverse events (two cycles) and
other reasons (seven cycles: patient convenience, five
cycles; surgery, two cycles). The dose of both irinotecan
and 5-FU was reduced in 34 cycles (16%), due to haema-
tological toxicity (15 cycles), non-haematological adverse
events (17 cycles), haematological and non-haematologi-
cal toxicity (one cycle) and weight loss (one cycle).
Haematological toxicity
Phase I
Neutropenia was the main adverse event. At dose level I,
grade 3–4 neutropenia occurred in 83% (5/6) of patients
(Table 3). The median time to neutrophil nadir was 13
days. The median durations of grade 3 and grade 4 neutro-
penia were one day and two days, respectively. At dose
level II, grade 3–4 neutropenia occurred in 63% (5/8) of
patients (Table 3). The median time to neutrophil nadir
was 20.5 days. At dose level I, grade 3–4 thrombocytope-
nia occurred in 17% (1/6) of patients. At dose level II, no
grade 3–4 thrombocytopenia was observed. Febrile neu-
tropenia was seen in one patient at dose level I, whilst one
patient had severe anaemia at dose level II (Table 3).
Phase II
Neutropenia was also the main adverse event for this
phase of the study, with grade 3–4 toxicity reported for
77% (38/49) of patients. Three patients experienced
febrile neutropenia. The median time to neutrophil nadir
was 15 days. The median duration of grade 3 and grade 4
neutropenia was one day. Grade 3–4 thrombocytopenia
and anaemia were infrequent and occurred in one and
two patients, respectively.
Non-haematological toxicities
Phase I
The most frequent grade 3–4 non-haematological adverse
events possibly or probably related to the treatment were
delayed diarrhoea, fatigue, pain, stomatitis, alopecia, nau-
sea, anorexia, vomiting, fever and infection. Grade 3–4
adverse events possibly or probably related to treatment
included delayed diarrhoea (57% of patients), fatigue
Table 2: Dose-limiting toxicity during first cycle of irinotecan combined with 5-FU/FA Mayo Clinic schedule according to dose levels in 
phase I study (n = 14)
Dose level I II Overall
Irinotecan (mg/m2) 250 300 250/300
5-FU (mg/m2) 425 425 425
FA (mg/m2)2 0 2 0 2 0
No. of cycles:
Total number 18 42 60
Median [range] 3 [1–6] 6 [2–8] 4 [1–-8]
No. of patients 6 8 14
Dose limiting toxicity (grade)*:
Any grade 3–4 non-haematological 
toxicity:
448
Pain (3) - 1 1
Stomatitis (3) 1 - 1
Nausea (3) 2 - 2
Fatigue (3) 2 1 3
Pulmonary (4) 1 - 1
Diarrhoea (3–4) 2 3 5
Febrile neutropenia** 1 0 1
Grade 3–4 infection 0 0 0
Grade 3–4 neutropenia with 
severe infection
011
No. patients with at least one DLT 4 (67%) 4 (50%) 8 (57%)
*Patient may have more than one dose-limiting toxicity (DLT). **Fever ≥38.0°C with concomitant grade 3–4 neutropenia in the absence of 
documented infection.BMC Cancer 2004, 4:36 http://www.biomedcentral.com/1471-2407/4/36
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(36% of patients), stomatitis (36% of patients), and pain
(29% of patients) (Table 4). Hepatic tolerance was very
good (no grade 3/4 increase for transaminases).
Phase II
The safety profile of the recommended dose combination
was close to that observed for the phase I patients. Grade
3–4 adverse events related to study drugs included diar-
rhoea in 33% of patients, stomatitis in 26% of patients,
fatigue in 22% of patients, infection in 16% of patients,
nausea in 16% of patients, vomiting in 14% of patients,
and pain in 18% of patients (Table 4). Hepatic tolerance
was good: one patient had a grade 3 increase in alkaline
phosphatase and one had a grade 3 increase in bilirubin.
However, three (out of 49) patients died of neutropenic
septic shock during the first cycle due to probable or pos-
sible treatment-related toxicity (these deaths occurred
within the first fifteen days of treatment). One of these
patients had a WHO PS of 1 and two had a WHO PS of 2.
Efficacy results
Phase I
In the phase I part of the study, three eligible patients were
not evaluable for efficacy because two full cycles of treat-
ment were not completed (n = 1) and/or the method of
tumour assessment following treatment differed from that
used at baseline (n = 3). PRs were seen in 18% (2/11) of
evaluable patients (0/4 at dose level I and 2/7 at dose level
II). In addition, 45% of evaluable patients had at least sta-
bilisation of their disease (four MR and one SD).
Phase II
In the phase II part of the study, nine of the eligible
patients were not evaluable for efficacy because two full
Table 3: Haematological toxicity of irinotecan combined with 5-FU 425 mg/m2 and FA 20 mg/m2 Mayo Clinic schedule (worst grade by 
patient)
Dose 
level
Irinotecan 
(mg/m2)
No.      
of 
patients
Neutropenia grade Thrombocytopenia 
grade
Anaemia grade Febrile 
neutropenia
12 3 4 1234 1 234
Phase I I 250 6 0 1 1 4 2 0 1 0 2 3 0 0 1
II 300 8 1 0 3 2 1 0 0 0 0 2 0 1 0
Overall 14 1 
(7%)
1 
(7%)
4 
(29%)
6 
(43%)
3 
(21%)
01  
(7%)
02  
(14%)
5 
(36%)
01  
(7%)
1 (7%)
Phase II 250 49 3 
(6%)
6 
(12%)
7 
(14%)
31 
(63%)
8 
(16%)
1 
(2%)
01  
(2%)
11 
(22%)
9 
(18%)
2 
(4%)
03  ( 6 % )
Table 4: Most common grade 3–4 non-haematological toxicity possibly or probably related to irinotecan combined with 5-FU/FA Mayo 
Clinic schedule according to dose levels (worst grade by patient)
Dose level Phase I Phase II
I II Overall
Irinotecan (mg/m2) 250 300 250/300 250
5-FU (mg/m2) 425 425 425 425
FA (mg/m2) 2 02 02 02 0
Number of patients 6 8 14 49
Delayed diarrhoea 4 4 8 (57%) 16 (33%)
Fatigue 2 3 5 (36%) 11 (22%)
Pain 3 1 4 (29%) 9 (18%)
Stomatitis 4 1 5 (36%) 13 (26%)
Alopecia 1 0 1 (7%) 2 (4%)
Nausea 2 0 2 (14%) 8 (16%)
Anorexia 1 1 2 (14%) 0
Vomiting 1 0 1 (7%) 7 (14%)
Fever 0 1 1 (7%) 0
Infection 0 0 0 8 (16%)BMC Cancer 2004, 4:36 http://www.biomedcentral.com/1471-2407/4/36
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cycles of treatment were not completed (n = 8) and/or the
method of tumour assessment following treatment dif-
fered from that used at baseline (n = 9). Among evaluable
patients there were three CR and 10 PR, giving an overall
response rate of 36% (13/36) (29% in the ITT popula-
tion) (Table 5). Seven patients had a MR and nine patients
had SD, leading to 44% SD. The median duration of sta-
bilisation was 5.8 months (95% CI, 4.0–8.3 months). The
median duration of response was 10.4 months (95% CI,
5.9–11.1 months). The median TTP was 7.0 months (95%
CI, 4.5–10.1 months) in the evaluable population and 5.9
months (95% CI, 4.0–8.1 months) in the ITT population
(Figure 1). The median survival time was 12.0 months
(95% CI, 8.0–15.2 months) (Figure 2).
Discussion
The main objective of this multicentre, open phase I/II
study was to evaluate the efficacy of the combination of
irinotecan administered as a 30- to 90-minute IV infusion
combined with the commonly used 5-FU/FA Mayo Clinic
schedule (bolus infusion daily for five days, every four
weeks) in patients with advanced CRC after determina-
tion of the recommended dose in the phase I part of study.
Delayed diarrhoea was dose limiting at an irinotecan dose
level of 300 mg/m2 (dose level II) combined with 5-FU
425 mg/m2 and FA 20 mg/m2. The recommended dose for
the phase II part of the study was, therefore, irinotecan
250 mg/m2 combined with 5-FU 425 mg/m2 (as a 15-
minute IV bolus) and FA 20 mg/m2. At this dose level, 18
cycles of irinotecan were administered to six patients in
the phase I part of the study and 218 cycles to 49 patients
in the phase II part of the study. In the phase II study, the
median RDI was superior or equal to 87% for each drug.
The combination of irinotecan and 5-FU/FA demon-
strated clinical activity, as evidenced by an overall
response rate of 29% among the ITT population and of
36% among the evaluable population. This is similar to
the response rate reported recently in a phase II study of
an alternating regimen of irinotecan and the Mayo Clinic
schedule (30%) [23]. However, the response rate is lower
than that reported among the ITT populations of a phase
II study investigating the Nordic bi-weekly schedule of iri-
notecan/bolus FU/FA (39%) [24]. While our study was
being conducted, results were published from the two piv-
otal phase III randomised trials confirming the benefits of
irinotecan combined with either the bi-weekly de
Gramont or the weekly German A.I.O. (Arbeitsgemein-
schaft Internische Onkologie) infusional regimens (Euro-
pean trial) [21] or the weekly bolus Saltz regimen (North
American trial) [20] compared with 5-FU/FA alone. The
response rates in the ITT populations of the irinotecan-
containing arms of both trials (35% and 50%) were
higher than that seen in our current study. The median
TTP was similar in our study, the phase II study using the
alternating irinotecan/Mayo Clinic schedule and the
phase III trials (approximately 7.0 months). However, the
median survival time in the ITT populations were higher
in both the phase II alternating irinotecan/Mayo Clinic
study (17 months) [23] and the phase III trials (14.8 and
17.4 months) [20,21] than in our study (12.0 months).
One possible explanation for the shorter median survival
time observed in our study could be the relatively lower
dose of irinotecan used (250 mg/m2 every four weeks),
compared with the doses used in the European trial (80
mg/m2/week or 180 mg/m2/2 weeks) [21] and the Amer-
ican trial (125 mg/m2/week) [20]. However, the recently
reported trial of alternating irinotecan/Mayo Clinic sched-
Table 5: Efficacy of irinotecan 250 mg/m2 combined with 5-FU 425 mg/m2 and FA 20 mg/m2 Mayo Clinic schedule in patients in phase II 
study
Evaluable population (n = 36) ITT population (n = 49)
No. % No. %
Complete response 3 8 3 6
Partial response 10 28 11 22
Minor response 7 19 7 14
Stable disease 9 25 10 20
Progressive disease 7 19 8 16
Not evaluable* - - 10 20
Overall response rate (95% CI), % 36 (21–54) 29 (16–42)
Median duration of response (95% CI), months 10.4 (5.9–11.1) 10.4 (4.5–11.1)
Median duration of stabilisation (95% CI), months 5.8 (4.0–8.3) 6.4 (4.0–8.3)
Median time to progression (95% CI), months 7.0 (4.5–10.1) 5.9 (4.0–8.1)
Median time of survival (range), months - 12.0 (8.0–15.2)
*Nine patients did not receive two full cycles and had method of measurement different from baseline and one patient had method of measurement 
different from baseline.BMC Cancer 2004, 4:36 http://www.biomedcentral.com/1471-2407/4/36
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ule used an irinotecan dose of 350 mg/m2 every six weeks
[23]. It is possible therefore that the schedule of adminis-
tration may be an influencing factor in outcome.
In the present study, neutropenia was the main toxicity.
The incidence of grade 3–4 neutropenia in the phase II
part of the study (77% of patients) was comparable to that
reported by Buroker et al. with the 5-FU/FA Mayo Clinic
schedule alone [4]. However, it was higher than that
reported with an alternating schedule of irinotecan/Mayo
Clinic schedule [23] and that reported by Saltz et al. in
their phase III study comparing irinotecan/bolus 5-FU/FA
(54%) with 5-FU/FA Mayo Clinic schedule alone (66%)
[20]. Although the incidence of grade 3–4 delayed diar-
rhoea in the present study (33% of patients in the phase II
study) was comparable to that obtained with irinotecan as
a single agent [20,25,26], it was higher than that reported
with the alternating irinotecan/Mayo Clinic schedule
(22%) [23] and the Saltz irinotecan/bolus 5-FU/FA (23%)
regimen [20]. The incidences of grade 3–4 infection (16%
of patients) and grade 3–4 stomatitis (26% of patients)
were also significant in the phase II part of our study.
Three treatment-related deaths occurred within the 60
days after the first infusion and were due to complications
following haematological toxicity. Since the initiation of
this trial, data have been published regarding the associa-
tion between some regimens of bolus 5-FU/FA, in combi-
nation with irinotecan or oxaliplatin, and early deaths of
patients [27-29]. Recommendations of an independent
panel for the use of irinotecan plus bolus 5-FU/FA include
the weekly assessment of patients, particularly up until
week 3 or 4 of treatment, and the prompt management of
diarrhoea and/or neutropenia and/or fever [28].
Kaplan-Meier plot of time to progression in ITT population Figure 1
Kaplan-Meier plot of time to progression in ITT population Three patients were censored (1 at 0.4 months, 2 at 0.5 months) 
due to deaths from neutropenic sepsis related to study treatment. The patient censored at 2.7 months died of bowel obstruc-
tion not related to study treatment.
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Conclusions
Although infusional regimens of 5-FU/FA in combination
with irinotecan seem to have better safety profiles than the
use of bolus 5-FU/FA, they are not always a practical ther-
apeutic option, and bolus-based regimens still have a role
to play in the treatment of metastatic CRC. The results of
the present phase I/II study show that the combination of
irinotecan (250 mg/m2) and the Mayo Clinic schedule of
bolus 5-FU/FA administered once every four weeks dem-
onstrated activity in the first-line treatment of metastatic
CRC. However, this regimen was associated with a rela-
tively high level of neutropenia. Three treatment-related
deaths amongst 49 patients were reported. Therefore, this
regimen requires a close follow-up of the patients. Infu-
sional 5-FU/FA in combination with irinotecan should be
the regimen of choice instead of bolus 5-FU/FA.
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